TBPH Theravance Biopharma, Inc. Insider Trading

Director Eran Broshy sold 59,000 shares (56.1% of holdings) across 3 trades on 2025-11-11 for $1.1M at blended $18.11

Eran Broshy, a director at Theravance Biopharma, executed three separate sales totaling 59,000 shares ($1,068,250.00) on 2025-11-11 at prices ranging from $17.00 to $18.50, reducing his holdings from 105,204 shares to 46,204 shares. The sale occurred near the 52-week high of $18.50, with the company trading at $17.95 currently and up +29.6% over the prior 30 days. Notably, Broshy's cross-ticker track record shows 2 prior buys with a 0.00% 90-day win rate and negative average 90-day returns, indicating a historical pattern of poor timing on open-market equity transactions. The fundamental context shows TBPH generated $20.0M in latest-quarter revenue with $3.6M net income but was unprofitable on a full-year basis, trading at a P/E of 30.95, which may signal valuation concerns at current levels.

10% owner Samaha Eli purchased 999,800 shares of TBPH at $7.80 for $7.8M, expanding stake to 9.51M shares despite stock down 33.9% from 52-week high.

Samaha Eli, a 10% shareholder, deployed $7,798,440.00 to acquire 999,800 shares at $7.80 on 2024-08-07, increasing his position by 11.7% to 9,511,150 shares. The timing aligns with a stock price under pressure: the current price of $7.66 reflects a -33.9% decline from the 52-week high of $11.59 and a -13.2% drop over the prior 30 days, signaling execution during a period of weakness. The company's fundamentals show ongoing challenges—annual revenue of $14,256,000.00 for the latest quarter with a net loss of $-16,529,000.00, and full-year net income was negative despite 11.8% annual revenue growth. Notably, Samaha's prior two purchases at this ticker (both on 2024-05-01) each achieved 15.0% gains at the 90-day mark, suggesting a pattern of well-timed entry points at this specific stock, though his cross-ticker track record shows broader strength with 16 prior buys averaging +21.3% 30d returns and +68.0% 90d returns at 100% win rate.